Emergent Biosolutions Inc Revenue Growth Rates (EBS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Emergent Biosolutions Inc   (NYSE: EBS)
 

EBS's Revenue Growth by Quarter and Year

Emergent Biosolutions Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/EBS/growth
https://api.csimarket.com/api/v1/companies/EBS/fundamentals
https://api.csimarket.com/api/v1/companies/EBS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
EBS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 110.00
2nd Quarter June 234.30
1st Quarter March 156.10
FY 500.40

EBSs Annual Revenue
Emergent Biosolutions Inc 's Revenue in the fiscal year 2025 $ 742.90 millions
Emergent Biosolutions Inc 's Revenue in the fiscal year 2024 $ 1,043.60 millions
Emergent Biosolutions Inc 's Revenue in the fiscal year 2023 $ 1,049.30 millions
Emergent Biosolutions Inc 's Revenue in the fiscal year 2022 $ 1,117.50 millions
Emergent Biosolutions Inc 's Revenue in the fiscal year 2021 $ 1,792.70 millions




EBS Revenue third quarter 2026 Y/Y Growth Comment
Emergent Biosolutions Inc reported drop in Revenue in the third quarter 2026 by -52.4% to $ 110.00 millions, from the same quarter in 2025.
The fall in the third quarter 2026 Emergent Biosolutions Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 15.71%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Revenue growth. While Emergent Biosolutions Inc ' s Revenue meltdown of -52.4% ranks overall at the positon no. 372 in the third quarter 2026.


EBS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -52.4 %
2nd Quarter June 66.29 %
1st Quarter March -29.75 %
FY   -

Financial Statements
Emergent Biosolutions Inc 's third quarter 2026 Revenue $ 110.00 millions EBS's Income Statement
Emergent Biosolutions Inc 's third quarter 2025 Revenue $ 231.10 millions Quarterly EBS's Income Statement


EBS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -53.05 %
2nd Quarter June 50.1 %
1st Quarter March 4.98 %
FY (Year on Year)   -


Back to EBS Growth rate Comparisons >> Back to EBS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #50
Healthcare Sector #97
Overall #372

Revenue Y/Y Growth Statistics
High Average Low
171.47 % 15.71 % -54.95 %
(Mar 31 2021)   (Mar 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #50
Healthcare Sector #97
Overall #372
Revenue Y/Y Growth Statistics
High Average Low
171.47 % 15.71 % -54.95 %
(Mar 31 2021)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Emergent Biosolutions Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
375.59 % 18.2 % -64.76 %
(Jun 30 2011)  


EBS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Emergent Biosolutions Inc disclosed fall in Revenue from the second quarter by -53.05% to $ 110.00 millions, from $ 234.30 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Emergent Biosolutions Inc 's Revenue growth quarter on quarter, overall rank is 242.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #66
Overall #242
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #66
Overall #242
Revenue Q/Q Growth Statistics
High Average Low
375.59 % 18.2 % -64.76 %
(Jun 30 2011)  


EBS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Emergent Biosolutions Inc disclosed fall in Revenue from the second quarter by -53.05% to $ 110.00 millions, from $ 234.30 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Emergent Biosolutions Inc 's Revenue growth quarter on quarter, overall rank is 242.


Emergent Biosolutions Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 649.10
Y / Y Revenue Growth (TTM) -17.72 %
Year on Year Revenue Growth Overall Ranking # 3455
Seqeuential Revenue Change (TTM) -15.72 %
Seq. Revenue Growth (TTM) Overall Ranking # 3239


Cumulative Revenue growth Comment
Emergent Biosolutions Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -17.72% year on year, at Sep 30 2026 compare to the -9.56% decrease at Jun 30 2026. If the Emergent Biosolutions Inc 's fiscal year would end at Sep 30 2026, annual Revenue would be $649 millions.

In the Healthcare sector 459 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1183 to 3455.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 138
Healthcare Sector # 460
Overall # 3455

Revenue TTM Y/Y Growth Statistics
High Average Low
57.04 %
 10.43 %
-42.61 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 138
Sector # 431
S&P 500 # 3239
Cumulative Revenue growth Comment
Emergent Biosolutions Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -17.72% year on year, at Sep 30 2026 compare to the -9.56% decrease at Jun 30 2026. If the Emergent Biosolutions Inc 's fiscal year would end at Sep 30 2026, annual Revenue would be $649 millions.

In the Healthcare sector 459 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1183 to 3455.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 138
Healthcare Sector # 460
Overall # 3455

Revenue TTM Y/Y Growth Statistics
High Average Low
57.04 %
10.43 %
-42.61 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 138
Sector # 431
S&P 500 # 3239




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EBS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Sutro Biopharma Inc -6.14%$ -6.138 millions
Zai Lab Limited-6.79%$ -6.794 millions


About Emergent Biosolutions Inc Revenue Growth Rates (EBS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Emergent Biosolutions Inc (CIK 1367644).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001367644-26-000112
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Emergent Biosolutions Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.